AMLEXANOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMLEXANOX (AMLEXANOX).
AMLEXANOX is a synthetic anti-inflammatory agent that inhibits the arachidonic acid pathway by reducing the activity of phospholipase A2 and lipoxygenase, leading to decreased production of leukotrienes and prostaglandins. It also inhibits mast cell degranulation and release of inflammatory mediators.
| Metabolism | Metabolized by conjugation, primarily to glucuronide metabolites; CYP450 enzymes are not significantly involved. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 60-70% of absorbed dose); biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function. Clinically, this supports dosing 4 times daily for topical oral use. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution after topical oral administration is not well defined; after IV administration in animal studies, Vd is approximately 0.5-1.0 L/kg, suggesting distribution into total body water. |
| Bioavailability | Systemic bioavailability after topical oral (mucoadhesive) administration is low (<5%) due to limited absorption across oral mucosa and first-pass metabolism. |
| Onset of Action | For topical oral (mucoadhesive) application: onset of clinical effect (reduction in ulcer pain and size) typically occurs within 1-3 days. |
| Duration of Action | Duration of action after topical oral application is approximately 4-6 hours, consistent with the need for 4 times daily dosing; effect persists with continued use. |
Apply a pea-sized amount (approximately 0.5 cm) of 5% oral paste to the affected area four times daily, after meals and at bedtime.
| Dosage form | PATCH |
| Renal impairment | No dose adjustment required based on renal function; drug is minimally systemically absorbed. |
| Liver impairment | No dose adjustment required based on hepatic function; drug is minimally systemically absorbed. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no dosing guidelines available. |
| Geriatric use | No specific dose adjustments required; use caution in elderly due to potential age-related oral mucosal changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMLEXANOX (AMLEXANOX).
| Breastfeeding | Unknown if excreted in human milk. Caution advised; M/P ratio not available. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required beyond routine prenatal care. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to amlexanox or any component of the formulation"]
| Precautions | ["Hypersensitivity reactions including rash and angioedema","Discontinue use if mucosal irritation worsens","Not for systemic use","Pregnancy Category B - weigh risk vs benefit"] |
| Food/Dietary | No significant food interactions. Avoid eating or drinking for at least 5 minutes after application to ensure proper adherence and drug action. |
| Clinical Pearls |
Loading safety data…
| Fertility Effects | No data on fertility in humans. Animal studies show no impairment. |
| Amlexanox is a topical anti-inflammatory agent used primarily for aphthous ulcers. It inhibits mast cell degranulation and leukotriene synthesis. For best results, apply at the first sign of ulcer formation. Avoid use in patients with known hypersensitivity to amlexanox or any component of the formulation. Not for ophthalmic or systemic use. Pain relief is typically noted within 1-2 days. |
| Patient Advice | Apply a small amount (approximately 0.5 cm) directly onto each ulcer after brushing teeth or eating. · Use 4 times daily, preferably after meals and at bedtime. · Do not eat or drink immediately after application to allow the paste to adhere. · Wash hands before and after application. · Notify your doctor if ulcers persist longer than 7 days or if you develop a rash or other allergic reactions. · Amlexanox is for topical oral use only; do not swallow or apply to eyes. |